Top list of clinical trial applicants, Zhengda Tianqing, Hengrui

In October, 59 clinical trials of chemical be were registered, 27 of which were consistency evaluation clinical trials; the hottest registered varieties in October were rivaroxaban tablets and pantoprazole sodium enteric coated tablets; in October, the most concerned bidding unit was Zhengda Tianqing Pharmaceutical Group Co., Ltd 1、 General situation of drug clinical trial registration in October 2019, there were 188 drug clinical trials publicly registered in CDE (11.24% month-on-month increase), including 139 chemical drugs (59 chemical be clinical trials, 80 chemical clinical applications), 37 biological products and 12 traditional Chinese medicine / natural drugs 2、 In October 2019, among the drug clinical trial varieties publicized by CDE, rivaroxaban tablets and pantoprazole sodium enteric coated tablets ranked first in three registration trials, among which two pantoprazole sodium enteric coated tablets were consistency evaluation clinical trials, and two Amoxicillin Capsules in top 5 were all consistency evaluation clinical trials, as shown in the figure below Note: this chart only lists the first five drug clinical registration varieties of this month, and there will be the same number of registration varieties not listed here later For more details, please click "read the original" to "drug intelligence data enterprise version of China clinical trial database" at the end of the article for inquiry PS1: the top rivaroxaban tablets are registered by the two bidding units of "Sanders (China) Pharmaceutical Co., Ltd." and "Hunan Jiudian Pharmaceutical Co., Ltd.", two of which are registered by "Sanders (China) Pharmaceutical Co., Ltd." and two of which are the bioequivalence tests of 10mg film coated tablets of rivaroxaban, which are taken orally once an empty stomach and after a meal respectively Proven PS2: pantoprazole sodium enteric coated tablets, which occupy the first place in the list, are also registered by "Hangzhou Kangenbei Pharmaceutical Co., Ltd." and "Shandong Yuxin Pharmaceutical Co., Ltd." two of them are registered by "Hangzhou Kangenbei Pharmaceutical Co., Ltd." and two of them are the bioequivalence test of pantoprazole sodium enteric coated tablets taken orally after meals and on an empty stomach Proven 3、 Consistency evaluation clinical trial In October 2019, 27 of the 188 clinical trial registrations (11.24% increase on a month on month basis) publicized by CDE (20.59% decrease on a month on month basis) were clinical trial registrations for conformity assessment, among which "Hangzhou Kangenbei Pharmaceutical Co., Ltd., Zhongshan lienpu Pharmaceutical Co., Ltd and Hebei Medical University pharmaceutical factory" three bidding units registered two different research contents for one variety of their respective units See the table below for details Note: this table only lists 27 be tests for consistency evaluation There are 32 be tests for deemed consistency evaluation this month that can be queried in "enterprise version of pharmaceutical intelligence data - Chinese clinical trial database" 4、 Drug clinical trial status According to the CDE announcement, by the end of October 2019, there are 4269 clinical trials of drugs in the completed state (134 clinical trials in the completed state only in October), of which 917 are consistency evaluation clinical trials (28 clinical trials in the completed state only in October); 4767 clinical trials of drugs are in the process of trial (including not yet recruited During recruitment and after recruitment), 397 of them are consistency evaluation clinical trials; 271 drug clinical trial applicants have applied for active suspension of trials, of which 15 new active tentative trials are added in October, as shown in the following figure for details 5、 Clinical trial applicants of great concern According to the analysis and statistics of pharmaceutical intelligence, in October 2019, the most concerned clinical trial bidding unit was Zhengda Tianqing Pharmaceutical Group Co., Ltd (ranked first in July), while Jiangsu Hengrui Pharmaceutical Co., Ltd., which ranked first in August and September, ranked second this month The bidding units of top 10 are listed here, as shown in the figure below Note: this chart only lists the top 10 interested bidding units of this month, and there will be the same number of bidding units not listed here For more details, please consult in the following ways Data source: China clinical trial database, CDE clinical trial registration and information publicity platform of pharmaceutical intelligence data Enterprise Edition; click the link "https://vip.yaozh.com/linchuangshiyan" to enter the pharmaceutical intelligence data enterprise edition of China clinical trial database responsible editor Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.